Greetings.

Busch Apothecary had a rather uneventful Q1 with hardly any reportable progress on key matters. Happily, Q2 brought with it, some important developments which gave us the basis for some strategic re-adjustments.

1. BIOPROSPECTING PERMIT APPLICATION.

The South African Department of Environmental Affairs informed us that our first Bioprospecting Permit (BP) application was gazetted in the Government Gazette of the Republic of South Africa. This is the final step in their process to ensure that the intended uses of our developmental products, are not another individual or community’s Intellectual Property or Indigenous Knowledge System. There were no such claims, of course.

We will soon celebrate this landmark achievement.

Without a BP we cannot conduct Research and Development(R and D) on any of the assets on our rich Pipeline.

In parallel to the South African Environmental Affairs BP applications, we have started a process through which we shall seek BP or equivalent permits from neighbouring States, in which our plants of interest grow. To this end, we have learnt of the relatively straightforward process in Zimbabwe where many of our Pipeline plants grow in the wild, under protection and under cultivation. We have a modestly sized, fenced and protected plot in the Masvingo District of Zimbabwe, on which several of our species currently grow.

The above exercise should offer us a viable alternative pathway for the acceleration of our R and D pace. Busch Apothecary needs a long term diverse source of plant materials and reduce our dependence on the South African environment.

Our Research and Development partners, Paarl based Afriplex, eagerly await the requisite Importation Permits and Bioprospecting Permits to start our processes with all the Regulatory documentation in place.

Over the next 8 weeks I shall be informing our collaborating organisations; the Innovation Hub, Gauteng Enterprise Propeller, CSIR and Afriplex (Pty) Ltd of these new developments and their impact on targets and timelines.

On the subject of Bioprospecting Permits, it appears like the completion of one application by the Department of Environmental Affairs takes between 18 and 24 months. I have therefore decided to invest time and resources over the next 6 months to ensure that by the end of Q 1 2017, we will have lodged BP applications for the top 10 developmental prospects on our Pipeline. This, I believe will take Busch Apothecary to a new level in the short term.

2. SEARCH FOR INVESTORS

We continue to search for substantial investors who may be interested in Busch Apothecary or any of the individual developmental assets in our rich product pipeline.

There have recently been exciting possibilities in this regard and hopefully we shall secure some investment in the short to intermediate term. I will naturally be delighted to make the announcement when the right time comes.

Thank you for your continued interest in Busch Apothecary. If the progress appears a tad slow, all I can say is that this is the “nature of the beast” however we have concrete plans to hasten the pace.

All the best for the future.

Yours sincerely.
Zi

As we approach the third anniversary of Busch Apothecary’s official existence, I am thrilled to invite you to page through our upgraded and updated website. I am tempted to boast about the new features and improvements but I will let you be the judge, please take some moments to go through it.

We plan to load more informative content for all visitors. The first instalment is a list of the top order in our developmental product pipeline “The Promise of Busch Apothecary” . Here, I would like to point out that there is a deliberate vagueness in some of the descriptions. The nature of our business requires that we keep all proprietary information confidential.

Knowledge and information constitute the very basis of the value of Busch Apothecary and must be protected. Furthermore, I will make an attempt to use non-scientific and/or medical terms for as long as the meaning of our messages is not lost in the process.

All visitors are invited to take an interest in our products, to see what interests or excites them and to get involved in whatever capacity they believe will be mutually beneficial to them and Busch Apothecary. Investors, scientists, marketers and all kinds of business people are more than welcome be part of the story of the growth of Busch Apothecary Pty Ltd.

Our collaborating organisations, namely the Afriplex Pty Ltd, the Innovation Hub, the Gauteng Enterprise Propeller and the Council for Scientific and Industrial Research (CSIR) are an important part of our evolution and for that we are most thankful. As we await our Bioprospecting Licences from the South African Department of Environmental Affairs, we thank them for their advice and engagement thus far.

Mr Tiger Chapanduka has been running our website since its launch and will continue to volunteer his generous advice and support, thank you Tiger.

Please visit us regularly for news, views and other updates.

Thank you for your interest in Busch Apothecary

Sincerely yours
Zi.
Chief Executive Officer on behalf of the Board of Directors.

As Busch Apothecary finalises the statutory, legal and regulatory preparations for the production of our first product, the medicinal herbal tea, Hi-tee®, we are most excited about the prospect of having Hi-tee® on the market. Consumers will soon be able to sample and experience the promise of the Busch Apothecary Pipeline.

We have more than fifty good quality products which have been used on a non-commercial basis over the past decades, and some, for centuries. In this short message, we invite all those who have an interest in Busch Apothecary, to have a look at the wide range of potential uses of our products. It is crucial to note that some of our products will be “consumer” products broadly classified as foods, beverages and “others”. This fact, as Hi-tee® proves, makes it possible for us to bring the products to market in a much shorter time than the lowest average time for products making any health benefit claims.

As the attached list shows, the Busch Apothecary product pipeline has both breadth and depth. Our intention is to issue updates on the progress in the development of each of our products, in due course.

Thank you for your on-going interest in Busch Apothecary’s affairs and progress.

Best regards
Zi.
CEO

Greetings.

I am delighted to announce that we have forged some very exciting alliances and collaboration agreements over the past few months. The most significant one is between Busch Apothecary (BApo) and Afriplex Pty Ltd.

Read more »

Warm winter greetings to all our clients, colleagues and associates.

The Medical Director and I have been busy with projects to move Busch Apothecary closer to bringing some products to the market and to move our developmental pipeline up the value chain.

Read more »

The first quarter of 2013 ended on a very exciting note with significant advances in our product pipeline. The South African National Biodiversity Institute has concluded work of the identification of the 23 plants which we submitted to them, the final report being delivered on 2nd April 2013. As we get absorbed in the exciting subjects of botany, phyto-chemisty and phyto-pharmaceuticals , Dr Rajen Misra, the Medical Director and I are like little fellows who have just unpacked a new video game. Move over Nintendo Wii, X-box, Playstation and the like! Literature review, in collaboration with our partners the Centre for Industrial and Scientific Research (CSIR) has revealed clear direction of development for some of our remedy sources and I will enumerate some of them below. However, a good number simply have no existing literature on any facts of interest and with those, compiling a cost-efficient developmental strategy will be a challenge, we have our work cut out for us. I outline some of our top order products in development below but first I will share the basis for some of our codes;

Read more »

To all our clients, colleagues and associates, I take this opportunity to wish you a most productive and prosperous 2013. Good health of body and mind should not be taken for granted and in that regard, I wish everyone a healthy and happy new year. It is only 6 months since we were officially registered as a company in South Africa and I am delighted to note that we have achieved some significant milestones.

Read more »